6606 — New Horizon Health Share Price
Last trade - 00:00Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 0.21% | ||
| Return on Equity | 4.37% | ||
| Operating Margin | 0.52% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CNYm | 18.82 | 58.27 | 70.57 | 212.76 | 764.96 | 1,940.1 | 3,062.38 | 152.51% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | +4.99 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
New Horizon Health Ltd is an investment holding company principally engaged in developing and commercializing innovative cancer screening products. The Company is primarily engaged in the research and development, clinical development, test operation and commercialization of screening products for colorectal cancer, gastric cancer, cervical cancer and others. The Company’s main products include home-based colorectal cancer screening tests ColoClear and Pupu Tube, stool-based self-conducted screening product for H. pylori UU Tube, and non-invasive urine-based home-use screening test for cervical cancer CerviClear. The Company mainly conducts its businesses in the domestic market.
Directors
- Yiyou Chen CHM (49)
- Yeqing Zhu CEO (49)
- Yu Gao CFO (38)
- Ning Lu CTO (50)
- Ming Wai Mok SEC
- Wing-Yu Leung NED (51)
- Naxin Yao NED (50)
- Kwok Tung Li NID (66)
- Hong Wu NID (63)
- Danke Yu NID (52)
- Last Annual
- December 31st, 2022
- Last Interim
- June 30th, 2023
- Incorporated
- June 7th, 2018
- Public Since
- February 18th, 2021
- No. of Employees
- 1,041
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- Stock Exchange of Hong Kong Limited
- Shares in Issue
- 448,754,608
- Address
- 13/F, T1 Building, HANGZHOU
- Web
- https://ir.newhorizonbio.com/
- Phone
- Auditors
- Deloitte Touche Tohmatsu
Upcoming Events for 6606
Similar to 6606
Acotec Scientific Holdings
Stock Exchange of Hong Kong Limited
Beijing Airdoc Technology Co
Stock Exchange of Hong Kong Limited
AK Medical Holdings
Stock Exchange of Hong Kong Limited
AMCO United Holding
Stock Exchange of Hong Kong Limited
Angelalign Technology
Stock Exchange of Hong Kong Limited
FAQ
As of Today at 22:16 UTC, shares in New Horizon Health are trading at HK$14.14. This share price information is delayed by 15 minutes.
Shares in New Horizon Health last closed at HK$14.14 and the price had moved by -49.86% over the past 365 days. In terms of relative price strength the New Horizon Health share price has underperformed the FTSE Developed Asia Pacific Index by -49.29% over the past year.
The overall consensus recommendation for New Horizon Health is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreNew Horizon Health does not currently pay a dividend.
New Horizon Health does not currently pay a dividend.
New Horizon Health does not currently pay a dividend.
To buy shares in New Horizon Health you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of HK$14.14, shares in New Horizon Health had a market capitalisation of .
Here are the trading details for New Horizon Health:
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 6606
Based on an overall assessment of its quality, value and momentum New Horizon Health is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like New Horizon Health. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -20.3%.
As of the last closing price of HK$14.14, shares in New Horizon Health were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The New Horizon Health PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at HK$14.14.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
New Horizon Health's management team is headed by:
- Yiyou Chen - CHM
- Yeqing Zhu - CEO
- Yu Gao - CFO
- Ning Lu - CTO
- Ming Wai Mok - SEC
- Wing-Yu Leung - NED
- Naxin Yao - NED
- Kwok Tung Li - NID
- Hong Wu - NID
- Danke Yu - NID